Please login to the form below

Not currently logged in
Email:
Password:

multiple sclerosis

This page shows the latest multiple sclerosis news and features for those working in and with pharma, biotech and healthcare.

Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses

Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses

New post hoc data comes from phase 3 ASCLEPIOS trials. Novartis has revealed new post hoc data for its multiple sclerosis (MS) therapy Kesimpta only a few weeks after the drug ... months when compared to Sanofi’s Aubagio (teriflunomide) in a subgroup

Latest news

More from news
Approximately 93 fully matching, plus 511 partially matching documents found.

Latest Intelligence

  • What Hemingway got right about patient communications What Hemingway got right about patient communications

    as multiple sclerosis and migraine, to monitor their health and track the success of their medication.

  • The search for treatments for Parkinson’s disease The search for treatments for Parkinson’s disease

    and a decade as senior director of neurodegenerative diseases research at Merck Serono where he served as its leader for in vitro pharmacology in neurology, including in multiple sclerosis, Parkinson’s

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    of B and T cells outside the lymph nodes, to treat relapsing forms of multiple sclerosis. ... Despite the expectation that it will face intense competition in the crowded multiple sclerosis market, sales of $80m are forecast for this year, rising to

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Elsewhere, BMS will need new Celgene prospects like selective JAK2 inhibitor Inrebic (fedratinib) – the first new myelofibrosis therapy in a decade – as well as other new drug candidates like multiple sclerosis ... The following month J&J agreed to a

  • Case study: OptiMiSe for MS nurses Case study: OptiMiSe for MS nurses

    OptiMiSe was launched in 2016 to support Multiple Sclerosis Specialist Nurses (MSSNs) in the provision of individualised care to patients living with MS.

More from intelligence
Approximately 0 fully matching, plus 37 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 25 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 16 fully matching, plus 29 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics